RARE

Ultragenyx Pharmaceutical Inc.

RARE | News F | $42.37 -2.33% -2.38% 680K

(0.0% 1d) (-9.2% 1m) (0.3% 1y) (0.0% 2d) (-3.9% 3d) (-1.2% 7d) (-25.56% volume)
Earnings Calendar: 2023-11-08
Market Cap: $ 3,487,051,000
http://www.ultragenyx.com
Sec Filling | Patents | 740 employees

(US) Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. Mepsevii is an intravenous, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010 and is headquartered in Novato, CA.

acquisitions antibody genetic treatment injection

Drugs

CRYSVITA (Burosumab)
DOJOLVI (Triheptanoin)
MEPSEVII (vestronidase alfa)

add to watch list Paper trade email alert is off

Press-releases

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-04-19 (Crawled : 20:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| Email alert Add to watchlist
nasdaq grant

Ultragenyx Announces Positive Interim Phase 1/2 Data in Patients with Angelman Syndrome After Treatment with GTX-102
Published: 2024-04-15 (Crawled : 11:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| -15.13% | O: -10.79% H: 0.0% C: -3.75%
gtx-102 positive treatment

Ultragenyx Announces Update to Conference Call Timing to Discuss New Data from GTX-102 in Patients with Angelman Syndrome
Published: 2024-04-12 (Crawled : 20:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| Email alert Add to watchlist
gtx-102 conference update

Ultragenyx Announces Upcoming Data Presentations at American Academy of Neurology (AAN) 2024 Annual Meeting
Published: 2024-04-12 (Crawled : 12:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| -18.75% | O: -4.27% H: 0.0% C: 0.0%
meeting

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-03-22 (Crawled : 20:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| Email alert Add to watchlist
nasdaq grant

FibroBiologics Appoints Ruben A. Garcia as General Counsel
Published: 2024-03-06 (Crawled : 14:30) - prnewswire.com
FBLG | $10.01 -9.08% -9.99% 38K

| -2.4% | O: 5.38% H: 0.0% C: -9.22%
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| -17.68% | O: -0.1% H: 0.69% C: -0.31%

Mereo BioPharma to Participate in Fireside Chat at the Leerink Partners Global Biopharma Conference
Published: 2024-03-05 (Crawled : 12:30) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| -20.52% | O: -1.29% H: 1.2% C: -2.19%
MREO | $2.64 -0.38% -0.38% 910K

Health Technology

| -31.61% | O: 0.0% H: 1.04% C: -3.11%
conference biopharma global

Ultragenyx to Participate at Investor Conferences in March
Published: 2024-02-27 (Crawled : 22:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| -21.04% | O: 0.0% H: 1.53% C: -1.7%

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Published: 2024-02-23 (Crawled : 21:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| Email alert Add to watchlist
nasdaq grant

Ultragenyx Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Update
Published: 2024-02-15 (Crawled : 21:00) - globenewswire.com
RARE | News F | $42.37 -2.33% -2.38% 680K

Health Technology

| -8.41% | O: 1.6% H: 5.47% C: 4.09%
year update financial results

See all

Last 15 days Sec forms

File Id	Form	Published Date	Transaction Date	Direction	Code	Amount Transacted	Owned Amount
0000950170-24-045670	4	2024-04-18	2024-04-16	Sell	F	14	41366
0000950170-24-029040	4	2024-03-11	2024-03-07	Sell	S	7500	14860
0000950170-24-029040	4	2024-03-11	2024-03-07	Sell	S	2145	22360
0000950170-24-029040	4	2024-03-11	2024-03-07	Sell	S	2550	24505
0000950170-24-026672	4	2024-03-06	2024-03-01	Buy	A	34200	34200
0000950170-24-026672	4	2024-03-06	2024-03-01	Buy	A	19400	99766